- Home
- CAPT vs PULM Comparison
CAPT vs PULM Comparison
Compare CAPT & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAPT | PULM |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 9.4M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | CAPT | PULM |
|---|---|---|
| Price | $0.43 | $2.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 254.7K | 46.8K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5069.93 |
| 52 Week Low | $0.30 | $1.63 |
| 52 Week High | $1.93 | $9.37 |
Technical Indicators
Market Signals| Indicator | CAPT | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 44.94 | 41.17 |
| Support Level | $0.39 | $1.63 |
| Resistance Level | $0.58 | $5.05 |
| Average True Range (ATR) | 0.02 | 0.28 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 56.74 | 29.38 |
Price Performance
Historical ComparisonAbout CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).